Johnson & Johnson remains one of the most reliable dividend payers in the healthcare sector, having raised its payout annually for more than six decades. The company’s diversified pharmaceutical and medical device businesses provide steady cash flows that support one of the longest dividend growth streaks on the market.
The setup
J&J is both a Dividend Aristocrat and a Dividend King. The company has increased its dividend every year for over 60 consecutive years. This places it among an elite group of companies with half a century or more of uninterrupted payout growth. The stock has historically traded with a yield in the 2.5% to 3.5% range, though the exact figure depends on the current share price.
In 2026, J&J shares have performed well. The company’s pharmaceutical division continues to drive revenue through drugs for immunology, oncology, and neuroscience. The MedTech segment, which includes surgical devices and orthopedics, benefits from an aging population and rising procedure volumes.
Key numbers
| Ticker | JNJ |
| Sector | Healthcare / Pharmaceuticals |
| Dividend status | Dividend King (60+ years of increases) |
| Typical yield range | 2.5% – 3.5% |
| Forward P/E | ~15x – 17x |
| Market cap | Large-cap (S&P 500) |
| Annual income per $100K invested | ~$2,500 – $3,500 |
What to watch
The pharmaceutical pipeline is J&J’s primary growth engine. Darzalex in multiple myeloma, Stelara in immunology, and Tremfya in psoriasis continue to generate strong sales. However, patent cliffs remain a long-term risk. When blockbuster drugs lose exclusivity, revenue can decline sharply unless new products replace them.
The MedTech division offers defensive characteristics. Medical device demand is less cyclical than pharmaceutical pricing. An aging global population supports long-term volume growth in joint replacements, surgical tools, and vision products.
Talc litigation has been an overhang for years. While the company has reached settlement agreements, residual claims and legal costs can create earnings volatility. Investors should monitor quarterly reports for litigation-related charges.
Portfolio impact
A retiree with $500,000 allocated to Johnson & Johnson at a 3.0% dividend yield would receive approximately $15,000 in annual income. That covers a meaningful portion of typical healthcare expenses for seniors. The lower yield compared to REITs or utilities is offset by greater dividend safety and long-term capital appreciation potential.
For younger investors, J&J offers a balance of income and growth. The company’s pharmaceutical pipeline and MedTech expansion provide revenue growth that supports continued dividend increases. A 60-year track record of payout growth suggests management prioritizes shareholder returns through varying market conditions.
Morningstar data shows that J&J’s wide economic moat rating reflects its strong patent portfolio, brand loyalty, and scale advantages. These factors protect profitability and support the dividend over long time horizons.
Peer comparison
| Company | Ticker | Yield | Dividend Streak |
| Johnson & Johnson | JNJ | ~2.5-3.5% | 60+ years |
| Pfizer | PFE | ~5.5-6.5% | 14+ years |
| AbbVie | ABBV | ~3.0-3.5% | 50+ years |
| Merck | MRK | ~2.5-3.5% | 10+ years |
Risks to watch
Patent expiration is the biggest long-term risk. Stelara faces biosimilar competition in the coming years. J&J must replace lost revenue with new drug approvals or acquisitions.
Regulatory risk also matters. Pharmaceutical pricing remains a political focus. Any legislation that caps drug prices could compress margins across the industry.
Currency headwinds affect J&J more than domestic-only peers. Roughly half of revenue comes from outside the United States. A strong dollar reduces reported earnings.
Bottom line
Johnson & Johnson offers a rare combination of dividend reliability, healthcare exposure, and large-cap stability. The 60-year dividend growth streak reflects disciplined capital allocation and durable cash flows. Conservative investors seeking healthcare exposure with income should keep J&J on their watch list.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
